Company profile: Exact Sciences
1.1 - Company Overview
Company description
- Provider of cancer diagnostics, including Cologuard, a non-invasive at-home stool-based colorectal cancer screening test for individuals 45+, Riskguard hereditary cancer testing, Oncotype DX Breast Recurrence Score to assess recurrence and guide treatment for ER+/HER2- breast cancer, OncoExTra genomic profiling for therapy selection in advanced/metastatic cancer, and under-development Breast Radiation Score and colorectal cancer blood test.
Products and services
- Cologuard: A non-invasive, at-home stool-based colorectal cancer screening test for individuals aged 45+, engineered to facilitate early detection via self-collection
- Oncotype DX Breast Recurrence Score: A genomic test that delivers insights into breast cancer recurrence likelihood and guides treatment decisions for ER+/HER2- cases
- OncoExTra: A genomic profiling test that identifies actionable genetic mutations, supporting therapy selection for patients with advanced or metastatic cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exact Sciences
Aegera Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage targeted therapeutics addressing major unmet medical needs, with three programs in clinical development—two in oncology and one in neuropathic pain—and ongoing identification of novel development candidates based on core technologies. Part of Pharmascience Inc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aegera Therapeutics company profile →
Delphinus Medical
HQ: United States
Website
- Description: Provider of breast cancer screening solutions for hospitals and imaging clinics, developing, commercializing, and servicing the SoftVue 3D Whole Breast Ultrasound Tomography, a 3D whole breast ultrasound system for dense breast screening that increases cancer detection by 20% when used alongside mammography.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delphinus Medical company profile →
Checkpoint Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology and targeted oncology therapies in development, advancing a pipeline including cosibelimab (fully human anti-PD-L1 monoclonal antibody), olafertinib (oral third-generation irreversible EGFR inhibitor for NSCLC), CK-103 (BET bromodomain inhibitor), CK-302 (agonistic GITR antibody), and an anti-CAIX antibody for renal cell carcinoma, plus product purchases, in-licensing and co-development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Checkpoint Therapeutics company profile →
Nerio Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology for the life sciences sector; founded in 2019 and based in La Jolla, CA, USA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nerio Therapeutics company profile →
JW Holdings
HQ: South Korea
Website
- Description: Provider of prescription drugs, over-the-counter drugs, and medical equipment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JW Holdings company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exact Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exact Sciences
2.2 - Growth funds investing in similar companies to Exact Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exact Sciences
4.2 - Public trading comparable groups for Exact Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →